Clinical trials
Completed Diabetes Mellitus, Type 1 trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
47 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 3 |
| 2002 | 4 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 47 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novo Nordisk A/S | 10 |
| Eli Lilly and Company | 5 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 4 |
| AstraZeneca | 3 |
| Medtronic MiniMed, Inc. | 3 |
| Melbourne Health | 3 |
| Boehringer Ingelheim | 2 |
| Bayhill Therapeutics | 1 |
| Capillary Biomedical, Inc. | 1 |
| GeNeuro Australia PTY Ltd | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 1 | 47 |
| Diabetes Mellitus | 14 |
| Diabetes Mellitus, Type 2 | 6 |
| Diabetic Neuropathies | 2 |
| Hypoglycemia | 2 |
| Autoimmune Diseases | 1 |
| Diabetes Complications | 1 |
| Endocrine System Diseases | 1 |
| Genetic Predisposition to Disease | 1 |
| Glucose Intolerance | 1 |
Trials
Showing 1 to 25 of 47. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.